Xiaowei Liu

8.8k total citations · 1 hit paper
255 papers, 6.3k citations indexed

About

Xiaowei Liu is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, Xiaowei Liu has authored 255 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Molecular Biology, 74 papers in Surgery and 39 papers in Oncology. Recurrent topics in Xiaowei Liu's work include Neuroblastoma Research and Treatments (21 papers), Inflammatory Bowel Disease (18 papers) and Helicobacter pylori-related gastroenterology studies (15 papers). Xiaowei Liu is often cited by papers focused on Neuroblastoma Research and Treatments (21 papers), Inflammatory Bowel Disease (18 papers) and Helicobacter pylori-related gastroenterology studies (15 papers). Xiaowei Liu collaborates with scholars based in China, United States and United Kingdom. Xiaowei Liu's co-authors include Silvia S. Pierangeli, Ricardo Espinola, Fanggen Lu, E. Nigel Harris, Gary L. Anderson, Edward N. Harris, Mariano E. Vega-Ostertag, Margaret Colden‐Stanfield, Guillermina Girardi and Brenda J. Weigel and has published in prestigious journals such as Circulation, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Xiaowei Liu

235 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global liver disease burdens and research trends: Analysis from a Chinese perspective

2019 410 citations Xiaowei Liu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaowei Liu China	38	2.2k	1.2k	1.2k	1.0k	816	255	6.3k
Robert A. Swerlick United States	36	1.9k 0.9×	808 0.7×	1.6k 1.4×	502 0.5×	814 1.0×	136	6.0k
Shunichi Kumagai Japan	40	1.4k 0.6×	1.8k 1.5×	1.8k 1.5×	447 0.4×	575 0.7×	195	6.1k
Cynthia C. Nast United States	51	2.4k 1.1×	766 0.6×	1.6k 1.4×	1.1k 1.1×	451 0.6×	152	7.7k
Takahiko Horiuchi Japan	40	1.5k 0.7×	1.9k 1.5×	3.1k 2.7×	405 0.4×	724 0.9×	225	6.8k
Carlo Perricone Italy	49	1.1k 0.5×	2.8k 2.3×	2.4k 2.1×	661 0.6×	494 0.6×	241	6.8k
Johan van der Vlag Netherlands	62	4.9k 2.2×	1.3k 1.1×	3.1k 2.7×	777 0.8×	462 0.6×	205	10.7k
Heinz‐Peter Schultheiß Germany	65	3.5k 1.6×	957 0.8×	1.5k 1.3×	2.5k 2.4×	1.0k 1.3×	352	15.6k
Andrew P. Cope United Kingdom	49	1.9k 0.9×	2.3k 1.9×	4.0k 3.5×	619 0.6×	1.2k 1.5×	230	8.7k
Michel Malaise Belgium	46	1.9k 0.9×	4.2k 3.5×	1.6k 1.3×	1.1k 1.1×	700 0.9×	202	8.5k
Harald Gollnick Germany	56	2.1k 0.9×	793 0.7×	1.6k 1.4×	450 0.4×	919 1.1×	291	9.8k

Countries citing papers authored by Xiaowei Liu

Since Specialization

Citations

This map shows the geographic impact of Xiaowei Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaowei Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaowei Liu more than expected).

Fields of papers citing papers by Xiaowei Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaowei Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaowei Liu. The network helps show where Xiaowei Liu may publish in the future.

Co-authorship network of co-authors of Xiaowei Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaowei Liu. A scholar is included among the top collaborators of Xiaowei Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaowei Liu. Xiaowei Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pan, Bei, Ning Ma, Dan Li, et al.. (2025). The association of screen time and the risk of sleep outcomes: a systematic review and meta-analysis. Frontiers in Psychiatry. 16. 1640263–1640263.

Liu, Xiaowei, et al.. (2024). Heading estimation algorithm for pedestrian navigation using a dual-foot-mounted IMU with a millimetre wave radar. Measurement. 239. 115497–115497.

Chen, Qilei, et al.. (2023). Automatic disease detection in endoscopy with light weight transformer. Smart Health. 28. 100393–100393. 4 indexed citations

Zhang, Jingyuan, Lin Yang, Xiaochang Leng, et al.. (2023). Accuracy of intravascular ultrasound-derived virtual fractional flow reserve (FFR) and FFR derived from computed tomography for functional assessment of coronary artery disease. BioMedical Engineering OnLine. 22(1). 64–64. 2 indexed citations

Ding, Alexander, et al.. (2023). Deep learning for gastric location classification: An analysis of location boundaries and improvements through attention and contrastive learning. Smart Health. 28. 100394–100394. 2 indexed citations

Liu, Xiaowei, et al.. (2023). Fundamental crosstalk between circadian rhythm and the intestine in the pathogenesis of inflammatory bowel disease. Clinics and Research in Hepatology and Gastroenterology. 47(9). 102214–102214. 2 indexed citations

Lian, Guanghui, et al.. (2023). Pneumatosis intestinalis associated with α-glucosidase inhibitors: a pharmacovigilance study of the FDA adverse event reporting system from 2004 to 2022. Expert Opinion on Drug Safety. 1–10. 4 indexed citations

Peng, Yu, et al.. (2023). Progress and Clinical Applications of Crohn’s Disease Exclusion Diet in Crohn’s Disease. Gut and Liver. 18(3). 404–413. 2 indexed citations

Li, Genpeng, Wenjie Chen, Jing Huang, et al.. (2023). Exosome-mediated Delivery of miR-519e-5p Promotes Malignant Tumor Phenotype and CD8+ T-Cell Exhaustion in Metastatic PTC. The Journal of Clinical Endocrinology & Metabolism. 109(6). 1601–1617. 14 indexed citations

10.

Huang, Shanshan, et al.. (2021). Characteristics of malnutrition according to Global Leadership Initiative on Malnutrition criteria in non-surgical patients with inflammatory bowel disease. Nutrition. 94. 111514–111514. 13 indexed citations

11.

Cash, Thomas F., Elizabeth Fox, Xiaowei Liu, et al.. (2021). A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Pediatric Blood & Cancer. 68(9). e29065–e29065. 23 indexed citations

12.

Liu, Xiaowei, et al.. (2021). Psychosomatic Disorders in Patients with Gastrointestinal Diseases: Single-Center Cross-Sectional Study of 1186 Inpatients. Gastroenterology Research and Practice. 2021. 1–9. 7 indexed citations

13.

Zhou, Nan, et al.. (2021). Co‐occurrence of gut microbiota dysbiosis and bile acid metabolism alteration is associated with psychological disorders in Crohn's disease. The FASEB Journal. 36(1). e22100–e22100. 43 indexed citations

14.

Liu, Xiaowei. (2020). Exposure to Carcinogens and its effects in the Formation of Cancer. 6(2). 1–2. 2 indexed citations

15.

Cole, Kristina A., Sharmistha Pal, Rachel A. Kudgus, et al.. (2019). Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clinical Cancer Research. 26(6). 1213–1219. 48 indexed citations

16.

Schafer, Eric S., Rachel E. Rau, Stacey L. Berg, et al.. (2019). Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatric Blood & Cancer. 67(2). e28073–e28073. 52 indexed citations

17.

Schafer, Eric S., Rachel E. Rau, Stacey L. Berg, et al.. (2018). A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatric Blood & Cancer. 65(8). e27066–e27066. 14 indexed citations

18.

Jiang, Yali, Shiren Sun, Junlong Zhao, Yuanyuan Wang, & Xiaowei Liu. (2015). Effect of macrophage polarization on interstitial fibrosis in mouse unilateral ureteral obstruction model. 31(3). 208–213. 1 indexed citations

19.

Wang, Yaochun, Fei He, Fan Feng, et al.. (2010). Notch Signaling Determines the M1 versus M2 Polarization of Macrophages in Antitumor Immune Responses. Cancer Research. 70(12). 4840–4849. 380 indexed citations

20.

Wang, Shuang, et al.. (2009). Generation and Utilization of Anti-drug Monoclonal Antibodies for Screening of 36 Drug Users by Dot-ELISA. Hybridoma. 28(2). 145–148. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact